$MRK news and market catalysts

Merck Receives FDA Approval For Its Dual Oral Regimen Of WELIREG Plus LENMIVA For The Treatment Of Adult Patients With Advanced Renal Cell Carcinoma With A Clear Cell Component

FDA Approves Merck's Belzutifan With Lenvatinib For Advanced Kidney Cancer With Clear Cell Component

Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine

Merck Says FDA Approves Update To US Product Label For WINREVAIR For Injection, 45mg, 60mg, Based On The Phase 3 HYPERION Trial

Merck's Subcutaneous KEYTRUDA QLEX Approved In Japan For All Existing KEYTRUDA Indications

Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer

EU CHMP Adopts Positive Opinion Recommending Approval Of KEYTRUDA, Merck’s Anti-PD-1 Therapy, In Combination With Padcev As Neoadjuvant Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer

Merck & Co Exec Says Timing For Raising The $70B Forecast Is "To Be Determined" Adds "It's Coming"

HSBC Maintains Buy on Merck & Co, Raises Price Target to $172

Leerink Partners Maintains Outperform on Merck & Co, Raises Price Target to $161

Medicare’s $2,000 Drug Cap Is Getting Expensive — More Than 1 in 5 Seniors Hit It as Drug Spending Heads Toward $346 Billion

Guggenheim Maintains Buy on Merck & Co, Raises Price Target to $170

Wells Fargo Maintains Overweight on Merck & Co, Raises Price Target to $170

Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease?

Merck shares are trading higher after Argus Research and Wolfe Research raised their respective price targets on the stock.

Live On CNBC, Josh Brown Host Segment Titled “Josh’s Best Stocks In The Market: Merck"

Wolfe Research Maintains Outperform on Merck & Co, Raises Price Target to $180

Argus Research Maintains Buy on Merck & Co, Raises Price Target to $170

Court Rejects Merck’s Challenge to Medicare Drug Price Negotiation Program

Goldman Sachs Maintains Buy on Merck & Co, Raises Price Target to $160

BMO Capital Maintains Outperform on Merck & Co, Raises Price Target to $170

Merck and Moderna's Phase 3 Win Raises the Stakes for BioNTech and Roche (CORRECTED)

UBS Maintains Buy on Merck & Co, Raises Price Target to $175

This Merck Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Morgan Stanley Upgrades Merck & Co to Overweight, Raises Price Target to $179

Merck shares are trading higher after the company announced topline results from the Phase 3 INTerpath-001 trial. The trial met its primary and key secondary endpoint.

Merck and Moderna Release Landmark Personalized Cancer Therapy Trial Success, Stocks Soar

Merck And Moderna Announce Topline Results From The Phase 3 Interpath-001 Trial Evaluating Adjuvant Treatment With Intismeran Autogene In Combination With KEYTRUDA In Patients With Completely Resected Stage IIB-IV Melanoma; At A Pre-specified Interim Analysis, Intismeran In Combination With KEYTRUDA As Adjuvant Therapy Demonstrated Statistically Significant And Clinically Meaningful Improvements In RFS And DMFS Compared To KEYTRUDA Alone

Daiwa Capital Upgrades Merck & Co to Outperform, Raises Price Target to $143

Trump Cuts Core Childhood Vaccine Recommendations to 11, Bill Cassidy Says 'This Executive Order Is Wrong' (UPDATED)

Argus Research Maintains Buy on Merck & Co, Raises Price Target to $145

'Trump Administration Is Working On An Executive Order That Would Split Childhood MMR Vaccine Into Three Shots And Delivering Vaccines At Separate Medical Visits' - Axios

Merck Receives FDA Approval For Supplemental Biologics License Application For ENFLONSIA To Expand Indication To Prevention Of Respiratory Syncytial Virus Lower Respiratory Tract Disease In Children Under Two Years Of Age At Increased Risk For Severe RSV Disease; PDUFA Date Set For March 22, 2027

Why Merck Just Slashed Its Profit Outlook By Nearly 50%

Merck & Co Lowers FY2026 Adj EPS Guidance from $5.04-$5.16 to $2.66-$2.76 vs $2.76 Est; Raises FY2026 Sales Guidance from $65.800B-$67.000B to $66.300B-$67.300B vs $66.802B Est

Merck & Co Q2 Adj. EPS $(0.13) Beats $(0.27) Estimate, Sales $16.607B Beat $16.356B Estimate

Barclays Maintains Overweight on Merck & Co, Raises Price Target to $150

Rick Scott Warns Beijing's New Drug Rules Could Threaten US Medicine Supply: 'Stop Being Dependent on Communist China'

Merck Announces Strategy For Rapid, Broad And Sustainable Access To Its HIV-1 Prevention Pill Alimatravir In Low- And Middle-Income Countries

Merck Just Won The Race For The First Cholesterol Pill: What It Means For Your Heart And Your Portfolio

FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio

Merck Says FDA Approves LIPFENDRA Tablets 20 Mg As Adjunct To Diet And Exercise To Reduce Low-Density Lipoprotein Cholesterol In Adults With Hypercholesterolemia

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer

Merck shares are trading higher after the company announced the Phase 3 KEYNOTE‑C93 trial evaluating KEYTRUDA met its primary endpoint of progression-free survival.

Merck's Phase 3 KEYNOTE‑C93 Trial Evaluating KEYTRUDA Met Primary Endpoint Of Progression-Free Survival For Treatment Of Patients With Mismatch Repair Deficient Advanced Or Recurrent Endometrial Cancer

JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $140

BMO Capital Maintains Outperform on Merck & Co, Raises Price Target to $142